Bispecific antibodies, which feature two different antigen-binding sites in one molecule, have promising applications in cancer immunotherapy. Only 3 bispecific antibodies have received FDA approval - Janssen Pharma's Rybrevant to treat adults with locally advanced or metastatic non-small cell lung cancer; Amgen's Blincyto for the treatment of patients with Philadelphia chromosome-negative (Ph-) relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL); and Roche's Hemlibra for the treatment of patients with hemophilia.
F-star Therapeutics Inc. (FSTX), a clinical-stage biopharmaceutical company, is developing next generation bispecific immunotherapies to transform the lives of cancer patients. The lead drug candidate is FS118, a tetravalent bispecific antibody targeting lymphocyte-activation gene 3 (LAG-3; CD223) protein and programmed cell death ligand 1 (PD-L1; CD274).
For comments and feedback contact: editorial@rttnews.com
Business News
May 15, 2026 15:25 ET Apart from the confirmation of Kevin Warsh as the next Fed chair, the main news on the economics front this week included key price data from the U.S. and the first quarter economic growth figures from major economies. Both consumer prices and producer costs have started to reflect the effect of supply shocks due to the Middle East conflict. In Europe, GDP data was in focus, while inflation data from China dominated the news flow in Asia.